Varanasi News Magazine

Pertussis Pipeline Landscape Analysis of 10+ Companies by DelveInsight | Leading Companies – GC Pharma, and Others

 Breaking News
  • No posts were found

Pertussis Pipeline Landscape Analysis of 10+ Companies by DelveInsight | Leading Companies – GC Pharma, and Others

October 03
17:15 2022
Pertussis Pipeline Landscape Analysis of 10+ Companies by DelveInsight | Leading Companies - GC Pharma, and Others

DelveInsight’s, “Pertussis Pipeline Insight, 2022,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Pertussis pipeline landscape.


Pertussis Pipeline landscape is provided which includes the disease overview and Pertussis treatment guidelines. The assessment part of the Pertussis pipeline report embraces, in depth Pertussis commercial assessment and clinical assessment of the pipeline products under development. In the Pertussis Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pertussis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.


Key takeaways from the Pertussis Pipeline Report

  • DelveInsight’s Pertussis Pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for various indications.
  • Leading Pertussis Companies such as GC Pharma, Serum Institute of India, Bionet-Asia, and others are evaluating new Pertussis Pipeline to improve the treatment therapies.
  • Promising Pertussis Therapies in the pipeline in various stages of development include BPZE1, TQL1055, Acellular pertussis vaccine, and many others
  • DTap, a product of Bionet-Asia is in the Phase III stage of drug development process. DTaP is an acronym for Diphtheria tetanus acellular pertussis vaccine. It contains tetanus and diphtheria toxoids and acellular pertussis antigens. The vaccine works by producing an active immune response by developing antibodies and antitoxins against the acellular pertussis antigens and toxoids.
  • GC Pharma’s drug candidate GC 3111A is being developed a vaccine against Diphtheria, Pertussis, and Tetanus. The drug belongs to the class of bacterial vaccines and work as immunostimulants. Currently, GC 3111A is in the Phase II of drug development process.


Request a sample and discover the recent advances in Pertussis @ Pertussis Pipeline Outlook


The Pertussis Pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Pertussis, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Pertussis Pipeline Landscape.


Pertussis Overview

Pertussis, also known as whooping cough, is caused by a bacterium known as Bordetella pertussis and leads to a serious respiratory infection. In this disease, violent and uncontrollable coughing is experienced by patients which makes it difficult for them to breathe. Even though pertussis can affect people across any age group, it can be fatal for infants and young children.

Pertussis may start with symptoms that mimic common cold such as cough, common cold, and fever. Within the span of two weeks, a persistent and dry cough may develop which may hinder normal breathing of an individual. Some other symptoms related to Pertussis are dehydration, vomiting, and blue or purple skin around the mouth.


Pertussis Pipeline Therapeutics Analysis

There are approx. 10+ key companies which are developing the therapies for Pertussis. The companies which have their Pertussis drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, Bionet-Asia and others.


 Pertussis Pipeline Analysis Report

  • The Pertussis Pipelinereport provides detailed insights about emerging therapies for the treatment of Pertussis and the aggregate therapies developed by major pharma companies.
  • It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pertussis Treatment.
  • It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • The Pertussis Pipeline Report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Pertussis market.

The Pertussis Pipeline Report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.


Pertussis Emerging Drugs

  • Bionet-Asia
  • GC Pharma


Scope of the Pertussis Pipeline Report

  • Coverage- Global
  • Pertussis Pipeline Assessment by Phases- Late stage products (Phase III), Mid-stage products (Phase II), Early-stage product (Phase I) along with the details of, Pre-clinical and Discovery stage candidate, Discontinued & Inactive Candidates
  • Pertussis Pipeline Assessment by Route of Administration- Oral, Parenteral, Intravitreal, Subretinal, Topical, Molecule Type
  • Pertussis Pipeline Assessment by Molecule Type- Monoclonal Antibody, Peptides, Polymer, Small molecule, Gene therapy, Product Type
  • Pertussis Companies- GC Pharma, Serum Institute of India, Bionet-Asia, and many others
  • Pertussis Therapies- BPZE1, TQL1055, Acellular pertussis vaccine, and many others


Dive deep into rich insights for Pertussis Pipeline Assessment, Visit @ Pertussis Pipeline Therapeutics Assessment


Table of Content

  1. Introduction
  2. Executive Summary
  3. Pertussis: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Pertussis – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Pertussis Collaboration Deals
  9. Late Stage Products (Phase III)
  10. DTaP: Bionet Asia
  11. Mid Stage Products (Phase II)
  12. GC 3111A: GC Pharma
  13. Pre-clinical and Discovery Stage Products
  14. Inactive Products
  15. Pertussis Key Companies
  16. Pertussis Key Products
  17. Pertussis- Unmet Needs
  18. Pertussis- Market Drivers and Barriers
  19. Pertussis- Future Perspectives and Conclusion
  20. Pertussis Analyst Views
  21. Pertussis Key Companies
  22. Appendix


For further information on the Pertussis Pipeline therapeutics, reach out @ Pertussis Pipeline Landscape


About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States